BMRN
Price:
$84.08
Market Cap:
$16.01B
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcu...[Read more]
Industry
Biotechnology
IPO Date
1999-07-26
Stock Exchange
NASDAQ
Ticker
BMRN
According to BioMarin Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 16.13B. This represents a change of -5.08% compared to the average of 17.00B of the last 4 quarters.
The mean historical Enterprise Value of BioMarin Pharmaceutical Inc. over the last ten years is 16.20B. The current 16.13B Enterprise Value has changed 9.86% with respect to the historical average. Over the past ten years (40 quarters), BMRN's Enterprise Value was at its highest in in the June 2020 quarter at 22.92B. The Enterprise Value was at its lowest in in the September 2014 quarter at 10.87B.
Average
16.20B
Median
16.21B
Minimum
12.95B
Maximum
19.53B
Discovering the peaks and valleys of BioMarin Pharmaceutical Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 32.41%
Maximum Annual Enterprise Value = 19.53B
Minimum Annual Increase = -17.64%
Minimum Annual Enterprise Value = 12.95B
Year | Enterprise Value | Change |
---|---|---|
2023 | 18.49B | -5.33% |
2022 | 19.53B | 17.33% |
2021 | 16.65B | 2.25% |
2020 | 16.28B | 4.71% |
2019 | 15.55B | 0.88% |
2018 | 15.41B | -4.44% |
2017 | 16.13B | 15.01% |
2016 | 14.03B | -17.64% |
2015 | 17.03B | 31.54% |
2014 | 12.95B | 32.41% |
The current Enterprise Value of BioMarin Pharmaceutical Inc. (BMRN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
18.22B
5-year avg
17.30B
10-year avg
16.20B
BioMarin Pharmaceutical Inc.’s Enterprise Value is less than Seagen Inc. (42.84B), less than Alnylam Pharmaceuticals, Inc. (33.42B), greater than Exelixis, Inc. (7.21B), greater than Halozyme Therapeutics, Inc. (8.85B), greater than Arrowhead Pharmaceuticals, Inc. (3.15B), greater than Incyte Corporation (10.85B), greater than Ionis Pharmaceuticals, Inc. (8.54B), greater than Apellis Pharmaceuticals, Inc. (5.11B), greater than Vaxcyte, Inc. (11.96B), greater than Liquidia Corporation (568.30M), greater than Legend Biotech Corporation (10.04B), greater than Bio-Techne Corporation (11.61B), greater than Mereo BioPharma Group plc (582.99M), greater than Blueprint Medicines Corporation (6.16B), greater than Agios Pharmaceuticals, Inc. (2.44B), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than IVERIC bio, Inc. (5.14B), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Karuna Therapeutics, Inc. (12.43B),
Company | Enterprise Value | Market cap |
---|---|---|
42.84B | $43.15B | |
33.42B | $31.68B | |
7.21B | $7.17B | |
8.85B | $7.50B | |
3.15B | $2.76B | |
10.85B | $11.80B | |
8.54B | $6.86B | |
5.11B | $5.00B | |
11.96B | $12.45B | |
568.30M | $698.44M | |
10.04B | $9.90B | |
11.61B | $11.34B | |
582.99M | $664.26M | |
6.16B | $5.47B | |
2.44B | $2.46B | |
1.01B | $1.25B | |
5.14B | $5.51B | |
89.50M | $161.36M | |
12.43B | $12.60B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioMarin Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioMarin Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BioMarin Pharmaceutical Inc.'s Enterprise Value?
What is the highest Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 3-year average Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 5-year average Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?
How does the current Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN) compare to its historical average?